These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 34516677

  • 1. The role of histopathological and biochemical parameters for predicting metastatic disease on 68 Ga-PSMA-11 PET in prostate cancer.
    Aydos U, Çetin S, Akdemir ÜÖ, Budak FÇ, Ateş SG, Koparal MY, Gönül İI, Gülbahar Ö, Sözen S, Atay LÖ.
    Prostate; 2021 Dec; 81(16):1337-1348. PubMed ID: 34516677
    [Abstract] [Full Text] [Related]

  • 2. Risk of metastatic disease on 68 gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer.
    Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H, Yaxley WJ, Coughlin G, Yaxley AJ, Gianduzzo T, Kua B, McEwan L, Wong D.
    BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
    [Abstract] [Full Text] [Related]

  • 3. How accurate is 68Gallium-prostate specific membrane antigen positron emission tomography / computed tomography (68Ga-PSMA PET/CT) on primary lymph node staging before radical prostatectomy in intermediate and high risk prostate cancer? A study of patient- and lymph node- based analyses.
    Erdem S, Simsek DH, Degirmenci E, Aydin R, Bagbudar S, Ozluk Y, Sanli Y, Sanli O, Ozcan F.
    Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Jan; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Recurrent prostate cancer: combined role for MRI and PSMA-PET in 68Ga-PSMA-11 PET/MRI.
    Jannusch K, Bruckmann NM, Morawitz J, Boschheidgen M, Quick HH, Herrmann K, Fendler WP, Umutlu L, Stuschke M, Hadaschik B, Antoch G, Schimmöller L, Kirchner J.
    Eur Radiol; 2024 Jul; 34(7):4789-4800. PubMed ID: 38038758
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of Gallium-68 prostate-specific membrane antigen, positron emission tomography/computed tomography (GA-68 PSMA PET/CT) in recurrent prostate cancer: a retrospective review of initial clinical experience at Tygerberg Hospital.
    Sangiwa BA, Burger C, Ellmann A.
    Pan Afr Med J; 2024 Jul; 48():30. PubMed ID: 39220559
    [Abstract] [Full Text] [Related]

  • 9. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values.
    Rogic I, Golubic AT, Zuvic M, Smitran T, Jukic N, Gamulin M, Kastelan Z, Huic D.
    Nucl Med Rev Cent East Eur; 2024 Jul; 27(0):6-12. PubMed ID: 38680016
    [Abstract] [Full Text] [Related]

  • 10. Ga68-PSMA PET for lymph node staging in intermediate and high-risk prostate cancer patients undergoing robotic assisted radical prostatectomy.
    Spena G, Moretti TB, Dávila FS, Dos Anjos G, Khan I, Calace FP, Aveta A, Pandolfo SD, Tufano A, Izzo A, Farias A, Perdonà S, Maes K.
    Minerva Urol Nephrol; 2024 Aug; 76(4):467-473. PubMed ID: 39051893
    [Abstract] [Full Text] [Related]

  • 11. Direct Patlak Reconstruction of [68Ga]Ga-PSMA PET for the Evaluation of Primary Prostate Cancer Prior Total Prostatectomy: Results of a Pilot Study.
    Rasul S, Geist BK, Einspieler H, Fajkovic H, Shariat SF, Schmitl S, Mitterhauser M, Bartosch R, Langsteger W, Baltzer PAT, Beyer T, Ferrara D, Haug AR, Hacker M, Rausch I.
    Int J Mol Sci; 2023 Sep 05; 24(18):. PubMed ID: 37761975
    [Abstract] [Full Text] [Related]

  • 12. 68Ga-PSMA PET/CT in Patients with Rising Prostatic-Specific Antigen After Definitive Treatment of Prostate Cancer: Detection Efficacy and Diagnostic accuracy.
    Hamed MAG, Basha MAA, Ahmed H, Obaya AA, Afifi AHM, Abdelbary EH.
    Acad Radiol; 2019 Apr 05; 26(4):450-460. PubMed ID: 29935970
    [Abstract] [Full Text] [Related]

  • 13. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68 Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer.
    Franklin A, Yaxley WJ, Raveenthiran S, Coughlin G, Gianduzzo T, Kua B, McEwan L, Wong D, Delahunt B, Egevad L, Samaratunga H, Brown N, Parkinson R, Roberts MJ, Yaxley JW.
    BJU Int; 2021 Jan 05; 127(1):71-79. PubMed ID: 32524748
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic accuracy of 68 Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of 68 Ga-PSMA PET to mpMRI.
    Scheltema MJ, Chang JI, Stricker PD, van Leeuwen PJ, Nguyen QA, Ho B, Delprado W, Lee J, Thompson JE, Cusick T, Spriensma AS, Siriwardana AR, Yuen C, Kooner R, Hruby G, O'Neill G, Emmett L.
    BJU Int; 2019 Nov 05; 124 Suppl 1():42-49. PubMed ID: 31287613
    [Abstract] [Full Text] [Related]

  • 15. Clinical parameters and nomograms for predicting lymph node metastasis detected with 68 Ga-PSMA-PET/CT in prostate cancer patients candidate to definitive radiotherapy.
    Onal C, Ozyigit G, Oymak E, Guler OC, Hurmuz P, Tilki B, Reyhan M, Tuncel M, Akyol F.
    Prostate; 2021 Jul 05; 81(10):648-656. PubMed ID: 33949694
    [Abstract] [Full Text] [Related]

  • 16. Primary lymph-node staging with 68Ga-PSMA PET in high-risk prostate cancer: pathologic correlation with extended pelvic lymphadenectomy specimens.
    Corona-Montes VE, González-Cuenca E, Fernández-Noyola G, Olarte-Casas MA, Bobadilla-Salazar D, Medrano-Urtecho HM, Asimakopoulos AD.
    Urol Oncol; 2021 Aug 05; 39(8):494.e1-494.e6. PubMed ID: 33223371
    [Abstract] [Full Text] [Related]

  • 17. Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer.
    Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, Beer AJ, Wester HJ, Gschwend J, Schwaiger M, Maurer T.
    Eur Urol; 2016 Nov 05; 70(5):829-836. PubMed ID: 26795686
    [Abstract] [Full Text] [Related]

  • 18. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.
    Kabasakal L, Demirci E, Nematyazar J, Akyel R, Razavi B, Ocak M, Aygun A, Obek C, Kural AR.
    Nucl Med Commun; 2017 Feb 05; 38(2):149-155. PubMed ID: 27893589
    [Abstract] [Full Text] [Related]

  • 19. Correlations between whole body volumetric parameters of 68Ga-PSMA PET/CT and biochemical-histopathological parameters in castration-naive and resistant prostate cancer patients.
    Yildirim ÖA, Gündoğan C, Can C, Poyraz K, Erdur E, Kömek H.
    Ann Nucl Med; 2021 May 05; 35(5):540-548. PubMed ID: 33586097
    [Abstract] [Full Text] [Related]

  • 20. Predictive factors of tumor sink effect: Insights from 177Lu-Prostate-specific membrane antigen therapy.
    Tuncel M, Telli T, Tuncalı MÇ, Karabulut E.
    Ann Nucl Med; 2021 May 05; 35(5):529-539. PubMed ID: 33586096
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.